A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade

Haematologica. 2021 Feb 1;106(2):651-654. doi: 10.3324/haematol.2020.258426.

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
² Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA 02215.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215. Matthew_Davids@DFCI.HARVARD.EDU.

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Lymphocytic, Chronic, B-Cell*
Lymphoma*
Lymphoma, B-Cell, Marginal Zone* / drug therapy
Splenic Neoplasms* / drug therapy

Grants and funding